rosuvastatin and DVT
Last reviewed 01/2018
- in this trial design there were randomly assigned 17,802 apparently healthy
men and women with both low-density lipoprotein (LDL) cholesterol levels of
less than 130 mg per deciliter (3.4 mmol per liter) and high-sensitivity C-reactive
protein levels of 2.0 mg per liter or higher to receive rosuvastatin, 20 mg
per day, or placebo
- participants were followed for the first occurrence of pulmonary embolism or deep-vein thrombosis and performed analyses of the data on an intention-to-treat basis
- during a median follow-up period of 1.9 years (maximum, 5.0), symptomatic venous thromboembolism occurred in 94 participants: 34 in the rosuvastatin group and 60 in the placebo group. The rates of venous thromboembolism were 0.18 and 0.32 event per 100 person-years of follow-up in the rosuvastatin and placebo groups, respectively (hazard ratio with rosuvastatin, 0.57; 95% confidence interval [CI], 0.37 to 0.86; P=0.007)
- the study authors concluded that apparently healthy persons, rosuvastatin significantly reduced the occurrence of symptomatic venous thromboembolism
Reference: